ALENGHAT | Expanding Peptide Access Could Sideline Research
This July, the U.S. Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC), a panel of experts that provides medical advice to the FDA, debated whether seven popular peptides, or short chains of amino acids, should be allowed in compounded medications despite limited clinical evidence of their safety and…